Karl Bergman

Karl Bergman is the CEO of Elypta, a Swedish cancer diagnostics company focused on developing a novel and accurate metabolism-based liquid biopsy test for cancer detection.12

Professional Background

Karl has been serving as the CEO of Elypta since its inception in April 2017.12 Prior to this role, he held several positions:

• Chief Digital Officer at Praktikertjänst AB, Sweden's largest private healthcare provider
• Principal at Arthur D. Little's healthcare & life science practice
• Various roles at Arthur D. Little, including Manager, Consultant, and Business Analyst
• MBA Intern in Private Equity at Climate Change Capital Ltd
• Project manager at GöteborgBIO and MedCoast Scandinavia

Education

Karl Bergman has a strong educational background in bioengineering and business:

• MBA from the University of Cambridge (2012-2013)
• M.Sc. in Innovation & Entrepreneurship from Chalmers University of Technology
• M.Sc. in Bioengineering from Chalmers University of Technology (2000-2006)
• Studies at the University of Gothenburg and National University of Singapore

Current Focus

At Elypta, Karl is dedicated to bringing a novel and exceptionally accurate biofluid test for cancer to market.1 The company's approach involves measuring a unique panel of metabolites in blood and urine to identify distinct "signatures" of cancer using machine learning.3

Achievements

Under Karl's leadership, Elypta has achieved several milestones:

• Won the EU Horizon 2020 SME instrument phase 2 grant of EUR 2.35 million
• Initiated a large-scale study on kidney cancer diagnostics
• Received recognition at the Nordic Life Science Awards

Karl Bergman is known for his expertise in digital health and emerging technologies with a positive impact on health and the environment.1 He continues to be actively involved in the development and advancement of Elypta's cancer detection technology.